Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
GSK announced the company’s first step towards delivering ultra long-acting injectable HIV treatment.
Download (PDF - 136.6KB)GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director
GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director.
Download (PDF - 150.6KB)Statement: Zantac (ranitidine) litigation
GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord.
Download (PDF - 108.6KB)ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
Key abstracts to be presented at CROI 2024 by ViiV Healthcare and its study partners.
Download (PDF - 318.5KB)GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)
EAGLE-1 trial met its primary efficacy endpoint.
Download (PDF - 137.7KB)LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges
Full data set to be presented at an upcoming scientific conference.
Download (PDF - 147.7KB)GSK completes acquisition of Aiolos Bio
GSK has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company.
Download (PDF - 119.6KB)GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)
Download (PDF - 189.2KB)GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk
GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.
Download (PDF - 275.7KB)GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration
Shingrix already approved in China for adults aged 50 years and over.
Download (PDF - 145.0KB)DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma
Results from an interim analysis of the DREAMM-7 phase III head-to-head trial.
Download (PDF - 184.1KB)Statement: Zantac (ranitidine) litigation
GSK today confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court.
Download (PDF - 108.6KB)GSK delivers strong 2023 performance and upgrades growth outlooks
FY 2023 performance highlights
Download (PDF - 942.2KB)GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.
Download (PDF - 167.1KB)European Commission authorises GSK’s Omjjara (momelotinib)
First medicine in the EU specifically indicated for splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Download (PDF - 152.5KB)Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype
Mepolizumab is the first targeted IL-5 biologic available in China as an add-on maintenance treatment for severe eosinophilic asthma.
Download (PDF - 260.3KB)GSK enters agreement to acquire Aiolos Bio
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody.
Download (PDF - 235.3KB)GSK enters exclusive license agreement with Hansoh for HS-20093
Hansoh’s HS-20093 builds on GSK’s oncology portfolio of clinical-stage antibody-drug conjugates.
Download (PDF - 182.9KB)Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial
Results reinforce development approach of using Jemperli as a backbone in immuno-oncology-based combination therapies
Download (PDF - 203.3KB)Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk
Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59.
Download (PDF - 249.3KB)